Bormioli pharma

Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has successfully completed the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group announced in May 2024. The closing was preceded by the fulfillment of customary closing conditions.

Bormioli Pharma today announced a partnership with Chiesi, an international, research-focused biopharmaceutical company (Chiesi Group), to supply Carbon Capture PET bottles. These will be used to package a medication indicated for the prophylaxis and treatment of seasonal and perennial allergic rhinitis, as well as vasomotor rhinitis.

From 8th to 10th October in Milan (Fiera Milano, booth 20A2), the company will showcase EcoPositive, one of the widest pharma-grade low impact product ranges available on the market, featuring over 3,000 items.

Asamedic, a pioneer in emergency medical treatment of myocardial infarction, and Bormioli Pharma announce their partnership for the commercialization of Coxor™ 300mg Acetylsalicylic acid, revolutionary life-saving medication designed for emergency treatment of suspected acute myocardial infarction.

This important recognition places the leading pharma packaging manufacturer in the top 5% of all evaluated companies, showing improved performances on environmental safeguarding, workplace practices and corporate ethics.

Bormioli Pharma announced today the third edition of its Sustainability Report. This edition outlines and consolidates the strong progress Bormioli Pharma has made in promoting sustainable growth in the communities where the Company live and work and highlights its strong commitment to supporting the pharmaceutical industry in its transition towards environmentally friendly solutions.

This packaging innovation will be showcased at Pharmapack Europe 2024 (24th-25th January, Paris Expo, Porte de Versailles - booth B78-B79, Hall 7.2)

Bormioli Pharma will attend Pharmapack Europe 2024 in Paris (Paris Expo, Porte de Versailles - booth B78-B79).

The project is part of the Bormioli Pharma Invents innovation programme, which aims to provide concrete answers to some of the most important challenges in the pharmaceutical packaging sector.

The company displays its wide portfolio of product and services in Barcelona from 24th to 26th of October (Fira Barcelona Gran Via, Booth 2K30, Hall 3.0).

The competition, which aimed to innovate traditional CRC locking systems through the introduction of biometric technologies, attracted 37 design proposals from 24 countries worldwide.

The academy aims to train professionals specialised in the processing of plastics.

The two contests aim to explore how two digital technologies, such as augmented reality and biometric recognition, can impact the future of pharmaceutical packaging, improving drug delivery and patient safety. In addition to receiving a monetary prize, the winners will have the opportunity to contribute to the development of their project.

One of the main objectives is to cut CO2 emissions by 30% by 2030, while the target for the reduction of water consumption has been redefined (from -30% to -41%) in light of the significant improvements already achieved in 2022.

Learn more about what primary pharmaceutical packaging is, the types, the materials used in its production and the relevant regulations.

Patients' usage habits regarding injectables and topicals were investigated by means of one-to-one interviews and focus groups. The investigation brought to light critical issues and potential areas for development.

The company has invested in strengthening its tubular glass vials capabilities through advanced machinery, while upgrading its platform for molded glass, and expanding clean-room capabilities for the production of rubber stoppers.

The company will display its wide product range in Paris on 1st-2nd February (Porte de Versailles Expo, booth A68-A70). Bormioli Pharma will also showcase new prototypes, among which a connected medical device able to administer ophthalmic drugs through nebulization.

Bormioli Pharma has launched an experimental investigation to compare properties and performance between two types of 10 ml and 30 ml vials in 'Delta' molded glass and tubing glass: the results show that both solutions provide comparable benefits, depending on the drug and the production processes for which they are intended.

Bormioli Pharma and Pierre Fabre, a French pharmaceutical and dermo-cosmetic group present in more than 100 countries, are consolidating their partnership started in 2020 through an innovative initiative in eco-design and sustainable development.

Bormioli Pharma will attend at CPHI in Frankfurt (booth 30B20) showcasing a service-driven, innovative and sustainable product offer and reaffirming its positioning as “one-stop shop” partner for the pharma industry.

Bormioli Pharma has published its first Sustainability Report according to ESG criteria, a document that reports on the Group's activities in terms of social responsibility during 2021 and that sets medium and long-term improvement objectives in line with its mission: "Making health a positive practice, accessible to all and kind to the planet".

Bormioli Pharma has presented a set of data highlighting that pharma-grade, sustainable plastic packaging is able to fulfill the strictest requirements of the industry in terms of quality and safety.

Bormioli Pharma announces the launch of EcoPositive, a brand new label gathering all the sustainable packaging solutions manufactured by the company.